We have recently reported corroborating results on a xenograft model using NRAS-mutant melanoma cells: the co-inhibition of the MAPK/ERK pathway with trametinib and the MEK5/ERK5 cascade using the ERK5i XMD8-92 was effective in preventing melanoma expansion [37]. The gene discussed is MAP2K5; the disease is melanoma.